


Gut Microbiota and Metabolome Alterations Associated with Parkinson's Disease

Sarah Vascellari,^a Vanessa Palmas,^a Marta Melis,^b Silvia Pisanu,^a Roberto Cusano,^c Paolo Uva,^c Daniela Perra,^a Veronica Madau,^a Marianna Sarchioto,^{b,d,*} Valentina Oppò,^b Nicola Simola,^e Micaela Morelli,^e Maria Laura Santoru,^f Luigi Atzori,^f Maurizio Melis,^b Giovanni Cossu,^b  Aldo Manzin^a

^aDepartment of Biomedical Sciences, Section of Microbiology and Virology, University of Cagliari, Cagliari, Italy

^bNeurology Service and Stroke Unit, AO Brotzu Hospital, Cagliari, Italy

^cCRS4, Science and Technology Park Polaris, Piscina Manna, Pula, Cagliari, Italy

^dDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy

^eDepartment of Biomedical Sciences, Section of Neuropsychopharmacology, University of Cagliari, Cagliari, Italy

^fDepartment of Biomedical Sciences, Oncology and Molecular Pathology Unit, University of Cagliari, Cagliari, Italy

ABSTRACT Parkinson's disease is a neurodegenerative disorder characterized by the accumulation of intracellular aggregates of misfolded alpha-synuclein along the cerebral axis. Several studies report the association between intestinal dysbiosis and Parkinson's disease, although a cause-effect relationship remains to be established. Herein, the gut microbiota composition of 64 Italian patients with Parkinson's disease and 51 controls was determined using a next-generation sequencing approach. A real metagenomics shape based on gas chromatography-mass spectrometry was also investigated. The most significant changes within the Parkinson's disease group highlighted a reduction in bacterial taxa, which are linked to anti-inflammatory/neuroprotective effects, particularly in the *Lachnospiraceae* family and key members, such as *Butyrivibrio*, *Pseudobutyrvibrio*, *Coprococcus*, and *Blautia*. The direct evaluation of fecal metabolites revealed changes in several classes of metabolites. Changes were seen in lipids (linoleic acid, oleic acid, succinic acid, and sebacic acid), vitamins (pantothenic acid and nicotinic acid), amino acids (isoleucine, leucine, phenylalanine, glutamic acid, and pyroglutamic acid) and other organic compounds (cadaverine, ethanolamine, and hydroxy propionic acid). Most modified metabolites strongly correlated with the abundance of members belonging to the *Lachnospiraceae* family, suggesting that these gut bacteria correlate with altered metabolism rates in Parkinson's disease.

IMPORTANCE To our knowledge, this is one of the few studies thus far that correlates the composition of the gut microbiota with the direct analysis of fecal metabolites in patients with Parkinson's disease. Overall, our data highlight microbiota modifications correlated with numerous fecal metabolites. This suggests that Parkinson's disease is associated with gut dysregulation that involves a synergistic relationship between gut microbes and several bacterial metabolites favoring altered homeostasis. Interestingly, a reduction of short-chain fatty acid (SCFA)-producing bacteria influenced the shape of the metabolomics profile, affecting several metabolites with potential protective effects in the Parkinson group. On the other hand, the extensive impact that intestinal dysbiosis has at the level of numerous metabolic pathways could encourage the identification of specific biomarkers for the diagnosis and treatment of Parkinson's disease, also in light of the effect that specific drugs have on the composition of the intestinal microbiota.

KEYWORDS 16S RNA, gut microbiota, PD, metabolome

Citation Vascellari S, Palmas V, Melis M, Pisanu S, Cusano R, Uva P, Perra D, Madau V, Sarchioto M, Oppò V, Simola N, Morelli M, Santoru ML, Atzori L, Melis M, Cossu G, Manzin A. 2020. Gut microbiota and metabolome alterations associated with Parkinson's disease. *mSystems* 5:e00561-20. <https://doi.org/10.1128/mSystems.00561-20>.

Editor Vanni Bucci, University of Massachusetts Medical School

Copyright © 2020 Vascellari et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Aldo Manzin, aldomanzin@medicina.unica.it.

* Present address: Marianna Sarchioto, Institute of Molecular and Clinical Sciences, St George's University of London, London, United Kingdom.

Received 22 June 2020

Accepted 24 August 2020

Published 15 September 2020

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the intracellular accumulation of α -synuclein (α -syn) aggregates (Lewy bodies) at various levels of the cerebral axis, including the central nervous system (CNS) and the enteric nervous system (ENS) (1). Clinical and neuropathological evidence indicates that the neurodegenerative changes in PD are accompanied by gastrointestinal (GI) dysregulation; however, whether this precedes or follows motor impairment remains to be established (2). Constipation is the most common premotor symptom in PD; it can affect more than 70% of PD patients (3) and can promote pathogenesis more than 10 years before the onset of clinical symptoms (2). Nevertheless, accumulation and aggregation of misfolded α -syn in the gut, coupled with neurodegeneration in the ENS (4), seems to start up to 20 years before the onset of neurodegeneration in the CNS (5), thus supporting the "gut-to-brain" hypothesis (6). Interactions between the intestine and brain are known to be modulated by the intestinal microbiota through immunological, neuroendocrine, and direct neurochemical mechanisms (7). Gut bacteria and bacterial metabolites could play a role in the pathogenesis of PD by promoting a proinflammatory environment in the gut (8, 9). Furthermore, intestinal inflammation associated with dysbiosis may contribute to the misfolding of α -syn (10, 11).

Recently, different studies have described gut microbial alterations associated with PD patients. The results are somewhat heterogeneous, and there is no explicit agreement about which bacteria community might be involved (12–20).

Moreover, gut microbiota modifications could reflect changes in bacterial metabolites. To date, several studies have investigated the metabolomics profile of PD patients in different biological samples, such as cerebrospinal fluid, blood, and urine (21–26). However, only a few studies have explored the fecal metabolome that mirrors the status of colonic bacteria and also links the symbiotic microbiota and health. A better understanding of the microbiota and metabolomics profile in fecal samples could elucidate the interactions between host/bacterial metabolisms, gut microbes, and disease. In turn, this knowledge may provide critical information for the implementation of better diet in PD.

Therefore, this study aimed to investigate the composition and structure of the fecal microbiota in a cohort of Italian PD patients (PDs) compared to healthy subjects (HCs) using 16S rRNA gene sequencing. Furthermore, intending to understand the functional contribution of the microbial community, we used direct analysis of the fecal metabolome to identify potential metabolic alterations associated with the microbiota in PD patients.

RESULTS

Patients with Parkinson's disease display altered microbiota composition compared to healthy subjects. Characteristics of the 64 patients with PD and 51 HCs are shown in Table 1. The bacterial communities in the PD patients and controls were analyzed at different taxonomic levels. *Firmicutes*, *Bacteroidetes*, *Proteobacteria*, *Actinobacteria*, and *Verrucomicrobia* were the five most abundant phyla, and altogether, they comprised more than 96% of all sequences. We detected no significant differences between cases and controls in alpha-diversity (species richness of a group) indexes ($P > 0.05$) (data not shown). We also assessed potential community-level differences between samples using beta-diversity analysis, and the weighted and unweighted dissimilarity significantly differed between cases and controls ($R^2 = 0.079$, $P < 0.001$, weighted; $R^2 = 0.028$, $P < 0.001$, unweighted) (Fig. 1b and c). The Mann-Whitney U test followed by the Benjamini and Hochberg false discovery rate (FDR) correction test for multiple comparisons was implemented to identify the different taxa within the groups. The FDR-corrected significant differences were also plotted using linear discriminant analysis (LDA) effect size (LEfSe) method (Fig. 2). The relative abundance of each taxon in the two study groups is reported in Table 2. *Actinobacteria*, *Proteobacteria*, and *Verrucomicrobia* were significantly enriched in diseased subjects, while *Bacteroidetes* and *Cyanobacteria* were significantly decreased; also, members of the *Firmicutes* were

TABLE 1 Subject characteristics^a

Variable	PD patients (n = 64)	Control subjects (n = 51)
Age (yr), mean ± SD	71.39 ± 10.99	51.67 ± 12.42
BMI, mean ± SD	26.07 ± 4.18	23.70 ± 3.46
Sex, n (%)		
Male	44 (68.75)	31 (60.78)
Female	20 (31.25)	20 (39.22)
Constipation, n (%)	37 (57.81)	0 (0)
Coffee consumption, n (%)		
Yes	40 (62.50)	44 (86.27)
No	24 (37.50)	7 (13.73)
Smoking status, n (%)		
Yes	7 (10.94)	18 (35.29)
No	57 (89.06)	33 (64.71)
Phenotype, n (%)		
Tremor-dominant	22 (34.37)	
Rigid-akinetic	26 (40.63)	
Dyskinetic	16 (25.00)	
Treatment, n (%)		
L-DOPA	64 (100)	

^aPD, Parkinson's disease; n, case number; SD, standard deviation; BMI, body mass index; L-DOPA, L-3,4-dihydroxyphenylalanine.

decreased; however, there was no significant difference in distribution between the PD and HC groups ($P > 0.05$).

A total of 225 families in PDs and 217 in HCs were detected. The abundance of 16 families was significantly modified in PDs versus HCs. For instance, among the most relevant in PDs, *Verrucomicrobiaceae*, *Bifidobacteriaceae*, *Streptococcaceae*, and *Desulfohalobiaceae* were increased, while *Bacteroidaceae*, *Lachnospiraceae*, *Brevibacteriaceae*, and *Sphingobacteriaceae* families were reduced. Differences were also observed at the genus level (601 in PDs versus 563 in HCs). The microbiota of PD patients was characterized by significantly higher levels of several genera, such as *Akkermansia*,




FIG 1 Beta-diversity analysis was presented as a two-dimensional (2D) plot based on principal coordinate analysis (PCoA). The statistical significance was assessed using permutational multivariate analysis of variance (PERMANOVA). (a) Bray-Curtis ($P = 0.001$; $F = 4.217$; $R^2 = 0.036$); (b) UniFrac weighted ($P = 0.001$; $F = 9.628$; $R^2 = 0.079$); (c) UniFrac unweighted ($P = 0.001$; $F = 3.255$; $R^2 = 0.028$). CTRL, control.




FIG 2 LEfSE analysis. The plot was generated using a Galaxy computational tool. (a) The bar plots represent the significantly differential taxa between PD patients (green) and controls (ctrl) (red), based on effect size (LDA score [\log_{10}] > 2). Enriched taxa in PD patients (positive LDA score) and enriched taxa in controls (negative LDA score). Differences among classes were obtained by the Kruskal-Wallis test ($\alpha = 0.05$). (b) Cladogram showed the differences in enriched taxa in PD (green) versus enriched taxa in controls (red). Differences among classes were obtained by the Kruskal-Wallis test ($\alpha = 0.05$).

Escherichia, *Bifidobacterium*, *Streptococcus*, *Clostridium*, and *Serratia*. An increase in some genera, such as *Veillonella*, *Prosthecobacter*, *Enterobacter*, and *Slackia*, was also observed. In contrast, several genera were significantly reduced: *Bacteroides*, *Blautia*, *Lachnospira*, *Butyrivibrio*, *Roseburia*, *Pseudobutyrvibrio*, *Brevibacterium*, *Dolichospermum*, *Coprococcus*, and *Odoribacter*.

Interestingly, within *Firmicutes*, the major differences concerned *Lachnospiraceae*, whose different genera were significantly reduced in the PD group.

As for *Bacteroidetes*, the major reductions concerned *Bacteroidaceae* and members therein. An overview of abundant taxa of the gut microbiota composition from each PD and healthy subject is represented as a heat map using statistical analysis of metagenomic profiles (STAMP) software (Fig. 3).

The analysis for confounding factors was performed using the generalized linear model (GLM) that was adjusted for sex, age, body mass index (BMI), coffee consumption, and smoking. No differences were observed in terms of the Mediterranean diet among the different participants recruited for this study. GLM analysis confirmed only, in part, the results obtained by the univariate analysis, indicating that some confounding factors influenced the microbiota community of our samples. The statistically significant differences in the composition of the intestinal microbiota in the PD group compared to the HC group were, however, maintained at various taxonomic levels (Table 3). In particular, *Lachnospiraceae* was significantly depleted in PD patients.

TABLE 2 Statistically significant differences in bacterial taxa between PD patients versus healthy controls^a

Phylum	Family	Genus	↓ / ↑ ^b	MD ^c	PD (%) ^d	HC (%) ^d	P value	FDR-adjusted P value ^e
Firmicutes	Thermoanaerobacterales	Caldicellulosiruptor	↑	0.226	0.121	0.058	0.010	0.014
	Incertae sedis							
	Veillonellaceae	Veillonella	↑	0.599	1.994	0.277	0.000	0.000
	Clostridiaceae	Clostridium	↑	0.169	3.133	2.154	0.012	0.016
	Streptococcaceae		↑	0.526	1.737	0.155	0.000	0.000
		Streptococcus	↑	0.513	1.730	0.153	0.000	0.000
	Eubacteriaceae		↑	0.287	0.120	0.062	0.000	0.000
		Acetobacterium	↑	0.273	0.115	0.059	0.000	0.000
	Lachnospiraceae		↓	-0.253	8.000	12.460	0.001	0.002
		Anaerostipes	↑	-0.406	0.236	0.144	0.027	0.030
		Blautia	↓	-0.243	3.778	5.928	0.001	0.002
		Lachnospira	↓	-0.444	0.535	1.086	0.000	0.000
		Butyrivibrio	↓	-0.655	0.021	0.113	0.000	0.000
		Roseburia	↓	-0.668	1.066	1.777	0.000	0.000
		Pseudobutyrvibrio	↓	-0.562	0.160	0.444	0.000	0.000
		Coprococcus	↓	-0.409	0.522	0.954	0.003	0.005
Bacteroidetes			↓	-0.269	28.546	47.455	0.000	0.000
	Bacteroidaceae		↓	-0.297	17.454	29.910	0.000	0.000
		Bacteroides	↓	-0.297	17.454	30.383	0.000	0.000
	Odoribacteriaceae	Odoribacter	↓	-0.432	0.191	0.331	0.001	0.002
	Porphyromonadaceae	Parabacteroides	↓	-0.245	1.858	2.269	0.046	0.050
	Rikenellaceae		↑	1.460	0.112	0.000	0.000	0.000
	Sphingobacteriaceae		↓	-0.177	1.045	1.471	0.044	0.049
Proteobacteria			↑	0.177	10.548	6.542	0.020	0.023
	Desulfovibrionaceae	Desulfovibrio	↑	0.278	0.293	0.245	0.020	0.023
	Desulfohalobiaceae		↑	0.355	0.185	0.123	0.002	0.003
		Desulfonauticus	↑	0.304	0.184	0.122	0.002	0.003
	Sutterellaceae	Sutterella	↓	-0.643	0.258	0.819	0.000	0.000
	Alcaligenaceae		↓	-0.642	0.270	0.837	0.000	0.000
	Comamonadaceae		↓	-0.440	0.045	0.127	0.001	0.002
	Enterobacteriaceae	Enterobacter	↑	0.559	0.404	0.173	0.001	0.002
		Escherichia	↑	1.003	3.737	0.259	0.000	0.000
		Serratia	↑	1.011	0.672	0.050	0.000	0.000
		Klebsiella	↓	-0.723	0.668	0.961	0.000	0.000
		"Candidatus Blochmannia"	↓	-1.673	0.042	1.392	0.000	0.000
Actinobacteria			↑	0.313	5.524	2.263	0.002	0.003
	Bifidobacteriaceae		↑	0.362	4.191	1.289	0.014	0.018
		Bifidobacterium	↑	0.356	4.173	1.288	0.016	0.020
	Coriobacteriaceae		↑	0.240	0.944	0.562	0.012	0.016
		Slackia	↑	0.309	0.309	0.158	0.001	0.002
	Microbacteriaceae		↑	0.441	0.677	0.333	0.000	0.000
	Brevibacteriaceae		↓	0.288	0.072	0.121	0.000	0.000
Verrucomicrobia			↑	0.614	5.429	1.020	0.002	0.003
	Verrucomicrobiaceae		↑	0.629	5.396	1.009	0.006	0.008
		Akkermansia	↑	0.464	4.669	0.879	0.015	0.019
		Prostheco bacter	↑	0.511	0.133	0.022	0.000	0.000
Cyanobacteria			↓	-0.156	0.509	0.730	0.000	0.000
	Aphanizomenonaceae	Dolichospermum	↓	-1.152	0.009	0.391	0.000	0.000

^aThe results were obtained by Mann-Whitney U test performed on Statistical Package for the Social Sciences (SPSS) version 25.0, followed by the Benjamini and Hochberg false discovery rate (FDR) correction test for multiple comparisons.

^b ↓, Significantly reduced in PD patients; ↑, significantly increased in PD patients.

^cMD, mean difference between the logarithmic value of relative abundance in the PD and HC groups.

^dAverage relative abundance (as a percentage) of each taxon in the PD and HC groups.

^eFDR-corrected P values with FDR < 0.05.




FIG 3 Heat maps of microbiota composition in PD cases and controls performed using the statistical analysis of metagenomic profiles (STAMP) software. The results were tested for statistical significance by the Mann-Whitney U test (Statistical Package for the Social Sciences Version [SPSS] 25.0) (60).

Accordingly, *Blautia*, *Butyrivibrio*, and *Coprococcus* were significantly reduced in the same group of subjects, while the only alteration in terms of richness was observed in the *Veillonella* genus. Concerning *Proteobacteria*, “*Candidatus Blochmannia*” was significantly reduced in PD patients. Also, *Brevibacteriaceae* and *Brevibacterium* belonging to *Actinobacteria*, as well as *Dolichospermum* belonging to *Cyanobacteria*, were significantly reduced. In our work, *Bacteroidetes* and *Verrucomicrobia* did not show any significant difference as opposed to the results of the univariate analysis.

Evaluation of fecal metabolites reveals alterations in the gut metabolome in PD patients. We performed a direct evaluation of fecal metabolites by gas chromatography-mass spectrometry (GC-MS). A total of 90 metabolites were identified

TABLE 3 Statistically significant differences of gut microbiome in PD versus HC groups^a

Phylum	Family	Genus	↓ / ↑ ^b	MD ^c	P value	Bonferroni-adjusted P value ^d
Firmicutes	Lachnospiraceae	<i>Blautia</i>	↓	−0.567	0.009	0.002
		<i>Butyrivibrio</i>	↓	−0.596	0.007	0.010
		<i>Coprococcus</i>	↓	−0.951	0.004	0.003
		<i>Coprococcus</i>	↓	−0.873	0.039	0.019
	Veillonellaceae	<i>Veillonella</i>	↑	1.556	0.002	0.000
Proteobacteria	Enterobacteriaceae	" <i>Candidatus</i> Blochmannia"	↓	−1.62	0.000	0.000
Actinobacteria	Brevibacteriaceae		↓	−0.640	0.001	0.000
		<i>Brevibacterium</i>	↓	−0.640	0.001	0.000
Cyanobacteria	Aphanizomenonaceae	<i>Dolichospermum</i>	↓	−1.364	0.001	0.000

^aAnalysis of covariance (ANCOVA) performed using generalized linear model (GLM) followed by Bonferroni correction for multiple comparisons in Statistical Package for the Social Sciences version (SPSS) 25.0 for Windows. The differences in microbiota composition between PD patients versus HCs were adjusted for sex, age, BMI, coffee consumption, and smoking status covariates.
^b↓, Significantly reduced in PD patients; ↑, significantly increased in PD patients.
^cMD, mean difference between logarithmic value of relative abundance in the PD and HC groups.
^dBonferroni-corrected P values with P < 0.05.

that included organic compounds, lipids, amino acids, and vitamins. The results of the orthogonal partial least-square discriminant analysis (OPLS-DA) model obtained from the comparisons of PD and HC groups using multivariate statistical analysis (MVA) are shown in Fig. 4a. OPLS-DA model quality parameters (R2Y, 0.6; Q2, 0.36) and the respective permutation test (R2 intercept, 0.0, 0.335; Q2 intercept, 0.0, −0.187) are shown in Fig. 4b and c, displaying the statistical validity of the analysis and indicating distinct metabolic profiles in the two different groups (Fig. 4).




FIG 4 Metabolomics multivariate statistical analysis (MVA). (a) OPLS-DA score plots of PD patients versus control subjects. (b) Validation parameters. R2X and R2Y indicated the cumulative explained fraction of the variation of the X block and Y block for the extracted components. Q2 values indicated cumulative predicted fraction of the variation of the Y block for the extracted components. R2 and Q2 intercept values are indicative of a valid model. (c) The permutation test was evaluated on the corresponding partial least-square discriminant analysis (PLS-DA) model.




FIG 5 Statistically significant metabolites in fecal samples of PD patients versus control subjects comparison. Discriminant metabolites obtained with the MVA underwent a Mann-Whitney U test with Holm-Bonferroni correction to determine which metabolites were statistically significantly different. The resulted metabolites obtained are shown and expressed on the y axes of the graphs as ranks (data transformation in which numerical or ordinal values are replaced by their rank when the data are sorted). The levels of significance are indicated by asterisks as follows: *, $P < 0.05$; **, $P < 0.01$.

Both up- and downregulation of metabolites were observed in the PD group compared to the HC group. The PD fecal samples clearly showed higher levels of several metabolites, such as cadaverine, ethanolamine, hydroxypropionic acid, isoleucine and leucine, phenylalanine, and thymine. In contrast, linoleic acid, oleic acid, nicotinic acid, glutamic acid, pantothenic acid, pyroglutamic acid, succinic acid, and sebacic acid were significantly decreased (Fig. 5).

Gut microbiota and fecal metabolite alterations are significantly related in PD patients. We correlated the different patterns of changes observed in the microbiota composition with microbiota metabolites in PD and HC groups.

The Spearman correlation analysis showed several significant associations of gut bacteria with metabolites in the two groups (Fig. 6). In PDs, *Lachnospira*, *Pseudobutyrvibrio*, and *Roseburia* genera showed strong positive correlations with nicotinic acid and pantothenic acid. Negative correlations were instead obtained between the *Serratia* genus and nicotinic acid, while *Bifidobacterium* correlated with pantothenic acid. *Streptococcaceae* and *Streptococcus* showed positive associations with cadaverine and, at the same time, a negative correlation with the *Sphingobacteriaceae* family. Negative correlations were also observed between the *Bifidobacteriaceae* family, and the related genus *Bifidobacterium*, with pyroglutamic acid. A positive correlation was obtained between this amino acid and the *Sphingobacteriaceae* family in the HC group. Conversely, negative correlations were observed with this amino acid and *Enterobacter* and *Serratia* genera. A similar trend was obtained between the *Sphingobacteriaceae* family and *Enterobacter* genus with glutamic acid. *Prostheco bacter* showed a positive correlation with leucine. Last, a positive correlation between *Bacteroidaceae* and linoleic acid was observed.

DISCUSSION

The present study confirmed and extended previous studies by showing that the overall composition of gut bacterial microbiota in PD patients and HCs is significantly




FIG 6 The heat maps represent Spearman correlation of the relative abundance of differential bacteria, selected by the linear discriminant analysis effect size (LEfSe) method followed by FDR correction test, and the concentrations of metabolites, selected by the MVA, underwent a Mann-Whitney U test with Holm-Bonferroni correction. (a) Heat map control ($n = 51$); (b) heat map PD ($n = 64$). The r values are represented by gradient colors, where red and green cells indicate positive and negative correlations, respectively. The asterisks indicate levels of significance as follows: *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$.

different. Moreover, evaluation of gut microbiota composition in relation to some confounding factors showed that some of these factors influenced the microbiota community, although the differences in the composition of the intestinal microbiota were maintained between PDs and HCs.

In recent years, the PD research community has given increasing attention to the alteration of gut microbiota because of its putative implication in the disease pathogenesis (27). Several reports on this topic have shown a different abundance of distinct bacterial taxa between PD patients and HCs. It has been postulated that this could be due to differences in the methodologies and patient enrollment criteria. This can also explain why data are only partially in agreement with each other (12–20).

The results presented herein show a distinctive profile of the gut microbial community in patients with PD compared to HCs. However, our results are in partial agreement with those previously produced by others. A possible explanation is that the statistical significance can be affected by the correction for confounders. As an example, in the case of *Firmicutes*, although univariate analysis showed a significant difference between patients and controls, after correction for different covariates (age, sex,

TABLE 4 PD-associated abundance of SCFA-producing bacteria^a

Phylum	Family	Genus	↓ / ↑ ^b	FDR-adjusted P value ^c	SCFA production
Actinobacteria	Bifidobacteriaceae		↑	0.003	Acetate
			↑	0.018	Acetate
		<i>Bifidobacterium</i>	↑	0.020	Acetate
Bacteroidetes	Bacteroidaceae		↓	0.000	Propionate
			↓	0.000	Propionate
	Odoribacteriaceae	<i>Bacteroides</i>	↓	0.000	Propionate
		<i>Odoribacter</i>	↓	0.002	Butyrate
Firmicutes	Clostridiaceae	<i>Clostridium</i>	↑	0.016	Butyrate
	Lachnospiraceae ^d		↓	0.002	Butyrate
		<i>Blautia</i> ^d	↓	0.002	Butyrate
		<i>Lachnospira</i>	↓	0.000	Butyrate
	Veillonellaceae	<i>Veillonella</i> ^d	↑	0.000	Acetate/propionate
Verrucomicrobia	Verrucomicrobiaceae		↑	0.003	Acetate/propionate
			↑	0.008	Acetate/propionate
		<i>Akkermansia</i>	↑	0.019	Acetate/propionate

^aAbundance of SCFA-producing bacteria in PD patients versus healthy controls using Mann-Whitney U test, followed by the Benjamini and Hochberg false discovery rate (FDR) correction test for multiple comparisons (FDR < 0.05).

^b ↓, Significantly reduced in PD patients; ↑, significantly increased in PD patients.

^c Bonferroni-corrected P values with P < 0.05.

^d Abundance of SCFA-producing bacteria in PD patients versus controls adjusted for sex, age, and BMI covariates using analysis of covariance (ANCOVA) performed using a generalized linear model (GLM) followed by Bonferroni correction for multiple comparisons in Statistical Package for the Social Sciences Version (SPSS) 25.0 for Windows.

BMI, coffee, and smoking), it did not match even with our data. However, in PD patients, the results showed a significant decrease in the abundance of taxa belonging to *Firmicutes*, particularly in *Lachnospiraceae* and key members therein, such as *Blautia*, *Coprococcus*, and *Butyrivibrio*. Our data are in agreement with other studies that showed a reduction of the *Lachnospiraceae* family and related genera in fecal samples from PD patients (12, 13, 18). Several members of the *Lachnospiraceae* family have progressively captured attention due to their ability to produce short-chain fatty acids (SCFAs) (28) (Table 4). Acetate, propionate, and butyrate are the primary SCFA molecules produced from gut bacteria fermentation and are endowed with anti-inflammatory properties. These metabolites appear to play an important role in orchestrating the function of the enteric nervous system and in promoting gastrointestinal integrity and motility (29). A reduction of SCFAs may also contribute to the development of gastrointestinal motility dysfunctions, thus highlighting the potential role of SCFA-producing bacteria in the pathogenesis of PD. We have investigated whether a reduction of the aforementioned SCFA producers correlates with the depletion of these metabolites in fecal samples from PDs. Although the levels of butyric acid, propionic acid, and acetic acid, in line with the microbiota profile relative to *Lachnospiraceae* members, were decreased in PD patients, no statistically significant variations were observed after FDR correction ($P > 0.05$). This finding is in contrast with the results by another research group that found a reduction in the fecal SCFAs (13). One possible explanation for this contrasting result may reside in the parallel increase we observed of *Veillonella*, *Akkermansia*, and *Clostridium* genera, which are known to produce acetate/propionate and butyrate. The enrichment of these bacteria may have caused a shift in the final levels of SCFAs, mirroring the balance between these taxa. Moreover, differences in the cohort studied, in terms of the number of participants (we considered a larger cohort) and other variables, including ethnic origins and host genetics, may also explain these discrepancies.

As mentioned earlier, we found an increase of *Veillonella* in the PD group. Our result extended, at the genus level, a previous report that showed an increase of the

Veillonellaceae family in PD patients (14). In agreement and extending the results of another study (30) reporting a reduction of the *Brevibacteriaceae* family, we also found a decrease of the *Brevibacterium* genus.

Among the different changes reported, the reduction in “*Candidatus Blochmannia*” and *Dolichospermum* genera in PD patients is of particular interest. It should be noted that to date, none of the studies carried out on the microbiota in PDs showed changes in *Cyanobacteria*, to which the *Dolichospermum* genus belongs. Members of *Cyanobacteria* produce a series of neurotoxins that are implicated in the protein misfolding and aggregation phenomenon that is seen in PD and other neurodegenerative disorders (31). However, the role of *Dolichospermum* is not clear, and the decrease in the abundance of *Dolichospermum* in PD patients deserves further investigation concerning its potential pathophysiological role and the effects of this reduction.

Finally, an evaluation of the fecal metabolic profile was made, and it highlighted interesting differences between PD patients and HCs. In particular, our data from direct analysis of fecal metabolites revealed that the metabolism of several amino acids, such as phenylalanine, leucine, and isoleucine, was significantly increased in PD patients. A recent paper showed that the levels of phenylalanine were increased in the plasma of subjects with PD (32). Other work has reported that amino acid-fermenting bacteria could modulate the distribution of amino acids in the gastrointestinal tract (33, 34) and that altered amino acid concentrations may reveal changes in energy metabolism (35). Accordingly, the data reported in the present study indicate a significant depletion of energy metabolism in PD.

Notably, PD patients revealed a significant reduction of the glutamic acid derivative pyroglutamic acid, whereas glutamic acid is a neurotransmitter implicated in PD pathogenesis (36).

Although the results concerning the levels of glutamic acid associated with PD are rather discordant among studies, some studies have suggested that a reduction of glutamic acid, which is also a precursor of glutathione, may reflect an increase in oxidative stress in the disease progression (37).

In addition to modification in amino acid metabolism, our findings highlighted an alteration of lipid metabolism.

Interestingly, the PD group was characterized by a reduction of linoleic acid and oleic acid. In particular, linoleic acid is an omega-6 polyunsaturated fatty acid (PUFA), and it has been associated with protective effects. Previous studies have proposed that a reduction of PUFA in PD models may reflect an excess of oxidative stress (38). In line with our data, some authors reported that the serum of PD patients showed decreased levels of several long-chain PUFAs, including linoleic acid (39).

In addition to the above reported metabolic changes, we found a reduction of B vitamins, such as nicotinic acid (vitamin B3) and pantothenic acid (vitamin B5). Both these vitamins can be directly produced and secreted by commensal bacteria in the gut; they can also elicit anti-inflammatory and antioxidant activity and show protective effects against neurodegenerative mechanisms (40, 41). The reported decrease in the levels of both B3 and B5 vitamins strongly correlated with *Lachnospira*, *Pseudobutyribrio*, and *Roseburia* genera. Several genera of intestinal *Firmicutes* bacteria express crucial factors for vitamin B3 synthesis (42, 43), suggesting that these bacteria might affect the metabolism and bioavailability of these vitamins in the gut. Vitamin B5 is the primary precursor of coenzyme A, and its deficiency might be involved in the alteration of the citric acid cycle, causing defective energy levels, a finding shared by several neurodegenerative disorders, such as PD, Huntington’s disease, and Alzheimer’s disease (44).

Concerning vitamin B3, other investigations have found a chronic vitamin B3 deficit in PD patients (45).

A toxic effect is instead ascribed to the polyamine cadaverine (46), a product of bacterial and human cometabolism (47), which we found to be increased in PD patients. A recent study revealed that cadaverine is involved in the inhibition of intestinal motility in a mouse model (48). We reported that an increased level of

cadaverine positively correlated with the *Streptococcaceae* family and the related genus *Streptococcus*, which are known to express cadaverine biosynthetic enzymes (49). An increase of cadaverine may also contribute to promoting a proinflammatory environment and motility dysfunctions of the gastrointestinal tract in PD.

Overall, our data highlight that microbiota modification correlated with numerous fecal metabolites, which is suggestive of the fact that PD is associated with gut dysregulation. Moreover, the present findings highlight that there is a mutualistic relationship between gut microbes and several bacterial metabolites that favor altered gut homeostasis.

In addition, we revealed alterations of several specific microbial taxa, including the reduction of the *Lachnospiraceae* family and genera therein (SCFA-producing bacteria), whose anti-inflammatory and protective role is well known within the organism.

Our study provides an overview of the complex alterations associated with PD. Since the interaction between gut microbiota and dopaminergic medication as well as anticholinergics has only recently been recognized (18, 50), more detailed investigations are needed and are in progress in order to establish the potential role played by gut bacteria on the therapeutic drugs in use (51) or, vice versa, a direct influence of the drugs themselves on microbiota modifications, as the drugs may hide the real microbiota composition in naive untreated PD patients. In addition, such studies might lead to the identification of novel candidate biomarkers for PD diagnosis and treatment and may provide a rationale for the development of new complementary therapeutic strategies for PD.

MATERIALS AND METHODS

Patients and samples. The institutional review boards and human subject committees at the participating institutions approved the study (protocol PG/2017/17817). Written or verbal informed consent was obtained from all enrolled participants: 64 patients with diagnosed PD and 51 healthy controls.

Patient inclusion criteria were as follows: diagnosis of idiopathic PD according to the UK Brain Bank criteria, Hoehn and Yahr stage I to IV, age between 45 and 85 years, and stable doses of dopaminergic treatment for at least 4 weeks before enrollment. The exclusion criteria were as follows: atypical or secondary Parkinsonism; the use of probiotic or antibiotic supplements for the 3 months before enrollment; the presence of a primary gastrointestinal disease; the concomitant presence of internal medicine, neurological, or unstable psychiatric illness together with severe cognitive impairment. Patients were evaluated by the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III and IV (motor part and motor fluctuations/dyskinesia) (52), and the following battery of clinical scales/questionnaires: nonmotor symptom scale (NMSS) (53), Scale for Outcome in Parkinson's disease-autonomic (SCOPA-AUT) (53), and Cognitive Assessment Montreal (MoCA) (54). Patients were classified as either tremor dominant (TD), with postural instability and gait difficulty (rigid-akinetic) (PIGD), or as dyskinetic patients. Stool samples from each subject were collected at outpatient facilities of the AO Brotzu and AOU Cagliari hospitals (Cagliari, Sardinia, Italy) and delivered to the laboratory within 3 h. The control group was composed of healthy participants, selected among spouses and family members of study patients.

Sample and library preparation and sequencing. DNA extraction and purification were performed as previously described (46). In particular, DNA extraction from thawed fecal samples was performed using the QIAamp DNA stool minikit following the manufacturer's instructions (Qiagen).

A total of 115 samples were sequenced using an Illumina MiSeq system. Sequences were assigned to operational taxonomic units (OTUs) using Quantitative Insights into Microbial Ecology (QIIME) (55). We performed a closed-reference OTU assignment using the "uclust" software (56) with a 97% sequence similarity threshold against Greengenes_13.8 97% OTU cluster (57) as a reference.

Barcoded amplicon libraries for sequencing on the Illumina MiSeq platform were generated using degenerate primers targeting the bacterial V3-V4 16S rRNA region with the Nextera index kit (Illumina), as previously described (46).

Data and statistical analysis. Analysis of the data generated on the MiSeq system was carried out using the BaseSpace 16S Metagenomics app (Illumina). Operational taxonomic unit mapping to the Greengenes database (V.13.8) was performed using the QIIME platform (V.1.8.0). Alpha-diversity analysis (Shannon, Simpson, Fisher, Chao1, and abundance-based coverage estimator [ACE]), was performed on the Microbiome Analyst tool (58). For beta-diversity analysis, weighted and unweighted UniFrac and Bray-Curtis distances were calculated using Adonis in vegan R package (59).

The Mann-Whitney U test followed by FDR correction test for multiple comparisons was used to identify bacterial taxa that were statistically different among PD patients and controls.

Linear discriminant analysis effect size (LEfSE) (<http://huttenhower.sph.harvard.edu/galaxy/>) analysis was performed on a Galaxy computational tool to estimate the effect size of each differentially abundant feature. Results were then corrected by FDR correction test for multiple comparisons. Heat maps of gut microbiota composition were generated using STAMP software.

The GLM was implemented, followed by Bonferroni correction for multiple comparisons using Statistical Package for the Social Sciences version (SPSS) 25.0 for Windows (60), to test for confounding factors. Only bacteria that were found to be significant at the univariate level after FDR correction were considered. No normally distributed variables had been normalized using their logarithmic value before performing GLM. The differences in microbiota composition between cases and controls were adjusted for sex, age, BMI, coffee consumption, and smoking status covariates.

Microbiota and metabolome analyses. Fecal microbiota analysis was investigated as previously described (46). For metabolomics, frozen feces were mixed in methanol solution and sonicated. After centrifugation, the supernatants were dried and derivatized with methoxyamine dissolved in pyridine (Sigma-Aldrich, St. Louis, MO, USA). *N*-Methyl-*N*-(trimethylsilyl)-trifluoroacetamide (Sigma-Aldrich, St. Louis, MO, USA) was added, and the samples were resuspended in hexane and filtered. Then, 20 μ l from each sample was used to create a pool for quality control.

For gas chromatography-mass spectrometry (GC-MS) analysis, 1 μ l of the derivatized sample was injected splitless into a 7890A gas chromatography coupled with a 5975C network mass spectrometer (Agilent Technologies, Santa Clara, CA, USA) equipped with a fused silica capillary column. The gas flow rate through the column was 1 ml/min. Identification of metabolites was performed using the standard National Institute of Standards and Technology NIST 08 standard and Golm Metabolome Database (GMD) mass spectra libraries and by comparison with authentic standards. Data processing was performed using a pipeline in KNIME.

The multivariate statistical analysis, PLS-DA, and OPLS-DA were performed using SIMCA-P software (ver. 14.0; Umetrics, Sweden). GraphPad Prism software (version 7.01; GraphPad Software, CA, USA) was used to perform the Mann-Whitney U test with Holm-Bonferroni corrected *P* values and Spearman correlations between the microbiome and the metabolome.

Data availability. Sequencing data have been deposited in the European Nucleotide Archive (ENA) under the accession number [PRJEB30401](https://www.ebi.ac.uk/ena/record/PRJEB30401). Metadata have been deposited under the accession number [PRJEB36138](https://www.ebi.ac.uk/ena/record/PRJEB36138).

ACKNOWLEDGMENTS

This research was partially supported by a Fondazione di Sardegna grant F71117000220002 to N.S. and grant BDS 2013.1325 to A.M. For this study, S.V. was funded by Regione Sardegna-POR FSE 2014-2020. The funding agencies had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

We thank the Associazione Sarda Malati Parkinson (ASAMPA) for contributing to patient enrollment and sample collection.

S. Vascellari (Data curation; Methodology; Formal Analysis; Visualization, Writing – original draft; Writing – review & editing), V. Palmas (Data curation; Formal Analysis; Methodology), M. Melis (Data curation; Formal Analysis), S. Pisano (Formal Analysis), D. Perra (Formal Analysis), V. Madau (Formal Analysis), M. L. Santoru (Formal Analysis), R. Cusano (Methodology), P. Uva (Data curation), M. Sarchioto (Data curation), V. Oppo (Data curation), N. Simola (Conceptualization; Writing – review & editing), M. Morelli (Conceptualization; Writing – review & editing), L. Atzori (Conceptualization; Writing – review & editing), M. Melis (Conceptualization; Writing – review & editing), G. Cossu (Conceptualization; Data curation; Writing – review & editing), A. Manzin (Project administration; Conceptualization; Supervision; Writing – original draft; Writing – review & editing).

REFERENCES

- Kalia LV, Lang A. 2015. Parkinson's disease. *Lancet* 386:896–912. [https://doi.org/10.1016/S0140-6736\(14\)61393-3](https://doi.org/10.1016/S0140-6736(14)61393-3).
- Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW. 2001. Frequency of bowel movements and the future risk of Parkinson's disease. *Neurology* 57:456–462. <https://doi.org/10.1212/WNL.57.3.456>.
- Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF. 2015. Gastrointestinal dysfunction in Parkinson's disease. *Lancet Neurol* 14:625–639. [https://doi.org/10.1016/S1474-4422\(15\)00007-1](https://doi.org/10.1016/S1474-4422(15)00007-1).
- Cersosimo MG, Benarroch EE. 2012. Pathological correlates of gastrointestinal dysfunction in Parkinson's disease. *Neurobiol Dis* 46:559–564. <https://doi.org/10.1016/j.nbd.2011.10.014>.
- Hawkes CH, Del Tredici K, Braak H. 2010. A timeline for Parkinson's disease. *Parkinsonism Relat Disord* 16:79–84. <https://doi.org/10.1016/j.parkreldis.2009.08.007>.
- Braak H, de Vos RAI, Bohl J, Del Tredici K. 2006. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. *Neurosci Lett* 396:67–72. <https://doi.org/10.1016/j.neulet.2005.11.012>.
- Mulak A, Bonaz B. 2015. Brain-gut-microbiota axis in Parkinson's disease. *World J Gastroenterol* 21:10609–10620. <https://doi.org/10.3748/wjg.v21.i37.10609>.
- Pfeiffer R. 2013. Beyond here be dragons: SIBO in Parkinson's disease. *Mov Disord* 28:1764–1765. <https://doi.org/10.1002/mds.25705>.
- Houser MC, Tansey MG. 2017. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis? *NPJ Parkinsons Dis* 3:3. <https://doi.org/10.1038/s41531-016-0002-0>.
- Devos D, Lebouvier T, Lardeux B, Biraud M, Rouaud T, Pouclet H, Coron E, Bruley des Varannes S, Naveilhan P, Nguyen JM, Neunlist M, Derkinderen P. 2013. Colonic inflammation in Parkinson's disease. *Neurobiol Dis* 50:42–48. <https://doi.org/10.1016/j.nbd.2012.09.007>.
- Olanow CW, Wakeman DR, Kordower JH. 2014. Peripheral alpha-

- synuclein and Parkinson's disease. *Mov Disord* 29:963–966. <https://doi.org/10.1002/mds.25966>.
12. Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, Mutlu E, Shannon KM. 2015. Colonic bacterial composition in Parkinson's disease. *Mov Disord* 30:1351–1360. <https://doi.org/10.1002/mds.26307>.
 13. Unger MM, Spiegel J, Dillmann K-U, Grundmann D, Philippel H, Bürmann J, Faßbender K, Schwiertz A, Schäfer K-H. 2016. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. *Parkinsonism Relat Disord* 32:66–72. <https://doi.org/10.1016/j.parkreldis.2016.08.019>.
 14. Li W, Wu X, Hu X, Wang T, Liang S, Duan Y, Jin F, Qin B. 2017. Structural changes of gut microbiota in Parkinson's disease and its correlation with clinical features. *Sci China Life Sci* 60:1223–1233. <https://doi.org/10.1007/s11427-016-9001-4>.
 15. Hopfner F, Künstner A, Müller SH, Künzel S, Zeuner KE, Margraf NG, Bork P, Wüllner U. 2017. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients. *Genome Med* 9:39. <https://doi.org/10.1186/s13073-017-0428-y>.
 16. Schepersjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E, Murros K, Auvinen P. 2015. Gut microbiota are related to Parkinson's disease and clinical phenotype. *Mov Disord* 30:350–358. <https://doi.org/10.1002/mds.26069>.
 17. Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, Molho E, Zabetian CP, Knight R, Payami H. 2017. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. *Mov Disord* 32:739–749. <https://doi.org/10.1002/mds.26942>.
 18. Petrov VA, Saltykova IV, Zhukova IA, Alifirova VM, Zhukova NG, Dorofeeva YB, Tyakht AV, Kovarsky BA, Alekseev DG, Kostriukova ES, Mironova YS, Izhboldina OP, Nikitina MA, Perevozchikova TV, Fait EA, Babenko VV, Vakhitova MT, Govorun VM, Sazonov AE. 2017. Analysis of gut microbiota in patients with Parkinson's disease. *Bull Exp Biol Med* 162:734–737. <https://doi.org/10.1007/s10517-017-3700-7>.
 19. Hasegawa S, Goto S, Tsuji H, Okuno T, Asahara T, Nomoto K, Shibata A, Fujisawa Y, Minato T, Okamoto A, Ohno K, Hirayama M. 2015. Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease. *PLoS One* 10:e0142164. <https://doi.org/10.1371/journal.pone.0142164>.
 20. Okuzumi A, Hatano T, Ueno SI, Ogawa T, Saiki S, Mori A, Koinuma T, Oji Y, Ishikawa KI, Fujimaki M, Sato S, Ramamoorthy S, Mohny RP, Hattori N. 2019. Metabolomics-based identification of metabolic alterations in PARK2. *Ann Clin Transl Neurol* 6:525–536. <https://doi.org/10.1002/actn3.724>.
 21. de Farias CC, Maes M, Bonifácio KL, Bortolasci CC, de Souza Nogueira A, Brinholi FF, Matsumoto AK, do Nascimento MA, de Melo LB, Nixdorf SL, Lavado EL, Moreira EG, Barbosa DS. 2016. Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson's disease and its progression: disease and staging biomarkers and new drug targets. *Neurosci Lett* 617:66–71. <https://doi.org/10.1016/j.neulet.2016.02.011>.
 22. Hatano T, Saiki S, Okuzumi A, Mohny RP, Hattori N. 2016. Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. *J Neurol Neurosurg Psychiatry* 87:295–301. <https://doi.org/10.1136/jnnp-2014-309676>.
 23. Trezzi JP, Galozzi S, Jaeger C, Barkovits K, Brockmann K, Maetzler W, Berg D, Marcus K, Betsou F, Hiller K, Mollenhauer B. 2017. Distinct metabolomic signature in cerebrospinal fluid in early Parkinson's disease. *Mov Disord* 32:1401–1408. <https://doi.org/10.1002/mds.27132>.
 24. Han W, Sapkota S, Camicioli R, Dixon RA, Li L. 2017. Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis. *Mov Disord* 32:1720–1728. <https://doi.org/10.1002/mds.27173>.
 25. Willkommen D, Lucio M, Moritz F, Forcisi S, Kanawati B, Smirnov KS, Schroeter M, Sigaroudi A, Schmitt-Kopplin P, Michalke B. 2018. Metabolomic investigations in cerebrospinal fluid of Parkinson's disease. *PLoS One* 13:e0208752. <https://doi.org/10.1371/journal.pone.0208752>.
 26. Mukherjee A, Biswas A, Das SK. 2016. Gut dysfunction in Parkinson's disease. *World J Gastroenterol* 22:5742–5752. <https://doi.org/10.3748/wjg.v22.i25.5742>.
 27. Flint HJ, Duncan SH, Scott KP, Louis P. 2015. Links between diet, gut microbiota composition and gut metabolism. *Proc Nutr Soc* 74:13–22. <https://doi.org/10.1017/S0029665114001463>.
 28. Soret R, Chevalier J, De Coppet P, Poupeau G, Derkinderen P, Segain JP, Neunlist M. 2010. Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats. *Gastroenterology* 138:1772–1782. <https://doi.org/10.1053/j.gastro.2010.01.053>.
 29. Lin A, Zheng W, He Y, Tang W, Wei X, He R, Huang W, Su Y, Huang Y, Zhou H, Xie H. 2018. Gut microbiota in patients with Parkinson's disease in southern China. *Parkinsonism Relat Disord* 53:82–88. <https://doi.org/10.1016/j.parkreldis.2018.05.007>.
 30. Brenner SR. 2013. Blue-green algae or cyanobacteria in the intestinal micro-flora may produce neurotoxins such as beta-N-methylamino-L-alanine (BMAA) which may be related to development of amyotrophic lateral sclerosis, Alzheimer's disease and Parkinson-Dementia-Complex in humans and Equine Motor Neuron Disease in horses. *Med Hypotheses* 80:103. <https://doi.org/10.1016/j.mehy.2012.10.010>.
 31. Zhao H, Wang C, Zhao N, Li W, Yang Z, Liu X, Le W, Zhang X. 2018. Potential biomarkers of Parkinson's disease revealed by plasma metabolic profiling. *J Chromatogr B Analyt Technol Biomed Life Sci* 1081–1082:101–108. <https://doi.org/10.1016/j.jchromb.2018.01.025>.
 32. Dai ZL, Wu G, Zhu WY. 2011. Amino acid metabolism in intestinal bacteria: links between gut ecology and host health. *Front Biosci (Landmark Ed)* 16:1768–1786. <https://doi.org/10.2741/3820>.
 33. Macfarlane GT, Allison C, Gibson SA, Cummings JH. 1988. Contribution of the microflora to proteolysis in the human large intestine. *J Appl Bacteriol* 64:37–46. <https://doi.org/10.1111/j.1365-2672.1988.tb02427.x>.
 34. Trupp M, Jonsson P, Ohrfelt A, Zetterberg H, Obudulu O, Malm L, Wuolikainen A, Linder J, Moritz T, Blennow K, Antti H, Forsgren L. 2014. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease. *J Parkinsons Dis* 4:549–560. <https://doi.org/10.3233/JPD-140389>.
 35. Figura M, Kuśmierska K, Bucior E, Szlufik S, Kozirowski D, Jamrozik Z, Janik P. 2018. Serum amino acid profile in patients with Parkinson's disease. *PLoS One* 13:e0191670. <https://doi.org/10.1371/journal.pone.0191670>.
 36. Lei S, Zavala-Flores L, Garcia-Garcia A, Nandakumar R, Huang Y, Madayiputhiyan N, Stanton RC, Dodds ED, Powers R, Franco R. 2014. Alterations in energy/redox metabolism induced by mitochondrial and environmental toxins: a specific role for glucose-6-phosphate dehydrogenase and the pentose phosphate pathway in paraquat toxicity. *ACS Chem Biol* 19:2032–2048. <https://doi.org/10.1021/cb400894a>.
 37. Hernandez S, Requejo C, Herran E, Ruiz-Ortega JA, Morera-Herreras T, Lafuente JV, Ugedo L, Gainza E, Pedraz JL, Igarua M, Hernandez RM. 2019. Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: the role of glia and Nrf2 regulation. *Neurobiol Dis* 121:252–262. <https://doi.org/10.1016/j.nbd.2018.10.001>.
 38. Schulte EC, Altmaier E, Berger HS, Do KT, Kastenmüller G, Wahl S, Adamski J, Peters A, Krumsiek J, Suhre K, Haslinger B, Ceballos-Baumann A, Gieger C, Winkelmann J. 2016. Alterations in lipid and inositol metabolisms in two dopaminergic disorders. *PLoS One* 11:e0147129. <https://doi.org/10.1371/journal.pone.0147129>.
 39. Xicoy H, Wieringa B, Martens GJM. 2019. The role of lipids in Parkinson's disease. *Cells* 8:27. <https://doi.org/10.3390/cells8010027>.
 40. Moretti R, Peinkhofer CB. 2019. B vitamins and fatty acids: what do they share with small vessel disease-related dementia? *Int J Mol Sci* 18:5797. <https://doi.org/10.3390/ijms180225797>.
 41. Rosemary A, Fricker RA, Green EL, Jenkins SI, Griffin SM. 2018. The influence of nicotinamide on health and disease in the central nervous system. *Int J Tryptophan Res* 11:1178646918776658. <https://doi.org/10.1177/1178646918776658>.
 42. Yoshii K, Hosomi K, Sawane K, Kunisawa J. 2019. Metabolism of dietary and microbial vitamin B family in the regulation of host immunity. *Front Nutr* 6:48. <https://doi.org/10.3389/fnut.2019.00048>.
 43. Patassini S, Begley P, Xu J, Church SJ, Kureishy N, Reid SJ, Waldvogel HJ, Faull RLM, Snell RG, Unwin RD, Cooper GJS. 2019. Cerebral vitamin B5 (D-pantothenic acid) deficiency as a potential cause of metabolic perturbation and neurodegeneration in Huntington's disease. *Metabolites* 9:113. [Crossref] <https://doi.org/10.3390/metabo9060113>.
 44. Bender DA, Earl CJ, Lees AJ. 1979. Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa. *Clin Sci (Lond)* 56:89–93. <https://doi.org/10.1042/cs0560089>.
 45. Santoru ML, Piras C, Murgia A, Palmas V, Camboni T, Liggi S, Ibba I, Lai

- MA, Orrù S, Blois S, Loizedda AL, Griffin JL, Usai P, Caboni P, Atzori L, Manzin A. 2017. Cross sectional evaluation of the gut-microbiome metabolome axis in an Italian cohort of IBD patients. *Sci Rep* 7:9523. <https://doi.org/10.1038/s41598-017-10034-5>.
47. Kovács T, Mikó E, Vida A, Sebő É, Toth J, Csonka T, Boratkó A, Ujlaki G, Lente G, Kovács P, Tóth D, Árkosy P, Kiss B, Méhes G, Goedert JJ, Bai P. 2019. Cadaverine, a metabolite of the microbiome, reduces breast cancer aggressiveness through trace amino acid receptors. *Sci Rep* 9:1300. <https://doi.org/10.1038/s41598-018-37664-7>.
 48. Sánchez M, Suárez L, Andrés MT, Flórez BH, Bordallo J, Riestra S, Cantabrana B. 2017. Modulatory effect of intestinal polyamines and trace amines on the spontaneous phasic contractions of the isolated ileum and colon rings of mice. *Food Nutr Res* 61:1321948. <https://doi.org/10.1080/16546628.2017.1321948>.
 49. de las Rivas B, Marcobal A, Carrascosa AV, Munoz R. 2006. PCR detection of foodborne bacteria producing the biogenic amines histamine, tyramine, putrescine, and cadaverine. *J Food Prot* 69:2509–2514. <https://doi.org/10.4315/0362-028x-69.10.2509>.
 50. Maini Rekdal V, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. 2019. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. *Science* 364:eaau6323. <https://doi.org/10.1126/science.aau6323>.
 51. van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, El Aidy S. 2019. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. *Nat Commun* 10:310. <https://doi.org/10.1038/s41467-019-08294-y>.
 52. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N. 2007. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. *Mov Disord* 22:41–47. <https://doi.org/10.1002/mds.21198>.
 53. Chaudhuri KR, Healy DG, Schapira AH, National Institute for Clinical Excellence. 2006. Non-motor symptoms of Parkinson's disease: diagnosis and management. *Lancet Neurol* 5:235–245. [https://doi.org/10.1016/S1474-4422\(06\)70373-8](https://doi.org/10.1016/S1474-4422(06)70373-8).
 54. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. 2005. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 53:695–699. <https://doi.org/10.1111/j.1532-5415.2005.53221.x>.
 55. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Peña AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. 2010. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods* 7:335–336. <https://doi.org/10.1038/nmeth.f.303>.
 56. Edgar RC. 2010. Search and clustering orders of magnitude faster than BLAST. *Bioinformatics* 26:2460–2461. <https://doi.org/10.1093/bioinformatics/btq461>.
 57. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, Huber T, Dalevi D, Hu P, Andersen GL. 2006. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. *Appl Environ Microbiol* 72:5069–5072. <https://doi.org/10.1128/AEM.03006-05>.
 58. Dhariwal A, Chong J, Habib S, King IL, Agellon LB, Xia J. 2017. MicrobiomeAnalyst: a web-based tool for comprehensive statistical, visual and meta-analysis of microbiome data. *Nucleic Acids Res* 45:W180–W188. <https://doi.org/10.1093/nar/gkx295>.
 59. Oksanen J, Kindt R, Legendre P, O'Hara B, Stevens MHH, Oksanen MJ, MASS Suggests. 2007. The vegan package. *Community Ecology Package* 10:719.
 60. IBM Corp. 2017. IBM SPSS statistics for Windows, version 25.0. IBM Corp., Armonk, NY.